Free Whitepaper

Where to Buy, Where to Build: An AI Investment Map for Clinical Development

Sponsors buying AI for clinical development today can find real value, and the products to capture it exist. The larger prize belongs to the builders and investors who close the gap: across every activity group, what limits AI's reach is what has been productized, not what the technology can do.

• How AI capability, available products, and economic value map across a trial's activities — and why today's buyable products reach about 5% of a Phase 3 trial's direct cost, against about 17% for present-day AI fully productized
• Where AI's impact has been independently evaluated, and what those data suggest
• What sponsors should weigh when pursuing AI value for cost and risk reduction — including where executional risk points somewhere cost alone does not
• Five moves to make now, with considerations for investors and AI builders

25 pages · PDF